Browsing by Author "Gonzalez, Robinson"

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Comparison of OLGA and OLGIM as predictors of gastric cancer in a Latin American population: the ECHOS Study
    (2024) Latorre Selvat, Gonzalo Ignacio; Silva Peña, Felipe Andres; Montero Jaras, Isabella; Bustamante Cartagena, Miguel Alonso; Dukes Berry, Eitan Ariel; Uribe Monasterio, Javier Andres; Corsi Sotelo, Oscar Felipe; Reyes Placencia, Diego Armando; Fuentes López, Eduardo; Pizarro Rojas, Margarita Alicia; Medel Jara, Patricio Andres; Torres, Javiera; Roa, Juan Carlos; Pizarro, Sebastian; Achurra Tirado, Pablo Andres; Donoso, Andres; Wichmann Pérez, Ignacio Alberto; Corvalan, Alejandro H.; Chahuan Abde, Javier Nicolas; Candia Balboa, Roberto Andres; Aguero, Carlos; Gonzalez, Robinson; Vargas, Jose Ignacio; Espino, Alberto; Camargo, M. Constanza; Shah, Shailja C.; Riquelme, Arnoldo
  • Thumbnail Image
    Item
    Gallbladder disease is associated with insulin resistance in a high risk Hispanic population
    (ELSEVIER SCIENCE BV, 2006) Nervi, Flavio; Miquel, Juan Francisco; Alvarez, Manuel; Ferreccio, Catterina; Garcia Zattera, Maria Jose; Gonzalez, Robinson; Perez Ayuso, Rosa Maria; Rigotti, Attilio; Villarroel, Luis
    Background/Aims: We tested whether cholesterol gallstone disease (GS) is associated to insulin resistance and serum C-reactive protein (CRP) in a high risk population.
  • No Thumbnail Available
    Item
    Identification of anti-Helicobacter pylori antibody signatures in gastric intestinal metaplasia
    (2023) Song, Lusheng; Song, Minkyo; Rabkin, Charles S.; Chung, Yunro; Williams, Stacy; Torres, Javier; Corvalan, Alejandro H.; Gonzalez, Robinson; Bellolio, Enrique; Shome, Mahasish; LaBaer, Joshua; Qiu, Ji; Camargo, M. Constanza
    Background Chronic Helicobacter pylori infection may induce gastric intestinal metaplasia (IM). We compared anti-H. pylori antibody profiles between IM cases and non-atrophic gastritis (NAG) controls. Methods We evaluated humoral responses to 1528 H. pylori proteins among a discovery set of 50 IM and 50 NAG using H. pylori protein arrays. Antibodies with >= 20% sensitivity at 90% specificity for either group were selected and further validated in an independent set of 100 IM and 100 NAG using odds ratios (OR). A validated multi-signature was evaluated using the area under the receiver operating characteristics curve (AUC) and net reclassification improvement (NRI). Results Sixty-two immunoglobulin (Ig) G and 11 IgA antibodies were detected in > 10%. Among them, 22 IgG and 6 IgA antibodies were different between IM and NAG in the discovery set. Validated antibodies included 11 IgG (anti-HP1177/Omp27/HopQ [OR = 8.1, p < 0.001], anti-HP0547/CagA [4.6, p < 0.001], anti-HP0596/Tip alpha [4.0, p = 0.002], anti-HP0103/TlpB [3.8, p = 0.001], anti-HP1125/PalA/Omp18 [3.1, p = 0.001], anti-HP0153/RecA [0.48, p = 0.03], anti-HP0385 [0.41, p = 0.006], anti-HP0243/TlpB [0.39, p = 0.016], anti-HP0371/FabE [0.37, p = 0.017], anti-HP0900/HypB/AccB [0.35, p = 0.048], and anti-HP0709 [0.30, p = 0.003]), and 2 IgA (anti-HP1125/PalA/Omp18 [2.7, p = 0.03] and anti-HP0596/Tip alpha [2.5, p = 0.027]). A model including all 11 IgG antibodies (AUC = 0.81) had better discriminated IM and NAG compared with an anti-CagA only (AUC = 0.77) model (NRI = 0.44; p = 0.001). Conclusions Our study represents the most comprehensive assessment of anti-H. pylori antibody profiles in IM. The target antigens for these novel antibodies may act together with CagA in the progression to IM. Along with other biomarkers, specific H. pylori antibodies may identify IM patients, who would benefit from surveillance.